We recently compiled a list of the Top 10 Medical AI Stocks on Wall Street’s Radar. In this article, we are going to take a ...

Leerink Partners analyst Puneet Souda maintained a Buy rating on Castle Biosciences (CSTL – Research Report) yesterday and set a price target ...

Leerink Partners lifted their target price on Vir Biotechnology from $18.00 to $20.00 and gave the company an “outperform” rating in a research report on Monday. HC Wainwright reiterated a ...

Vir Biotechnology (NASDAQ:VIR – Get Free Report) had its price objective raised by Leerink Partners from $18.00 to $20.00 in a research report issued to clients and investors on Monday ...

"Although this is the second quarter in a row of disappointing results, we expect 2025+ financial performance and pipeline news flow (specifically oral GLP-1 orforglipron Ph3 results) to be ...

A minor uptick in Leerink Partners’ price target to $87 followed AstraZeneca’s strong third-quarter performance, with revenue reaching $13.565 billion – exceeding projections by 4%.

Leerink Partners served as exclusive financial advisor to Banner and Skadden, Arps, Slate, Meagher & Flom LLP acted as legal advisor. To find out more about BAFIERTAM, please visit www.bafiertam.com.

On Monday, Progyny (NASDAQ:PGNY) shares saw a change in their market prospects as Leerink Partners adjusted the company's price target. Analysts at Leerink Partners increased the price target on ...

In a report released on January 9, Thomas Smith from Leerink Partners reiterated a Buy rating on Climb Bio (CLYM – Research Report). The company’s shares closed last Friday at $2.00.

For IDRx, Centerview Partners LLC is acting as exclusive financial advisor and Goodwin Procter LLP as legal counsel. For GSK, Leerink Partners LLC is acting as the exclusive financial advisor.